Graded murine wire-induced aortic valve stenosis model mimics human functional and morphological disease phenotype
Aortic valve stenosis (AS) is the most common valve disease requiring therapeutic intervention. Even though the incidence of AS has been continuously rising and AS is associated with significant morbidity and mortality, to date, no medical treatments have been identified that can modify disease progression. This unmet medical need is likely attributed to an incomplete understanding of the molecular mechanism driving disease development. To investigate the pathophysiology leading to AS, reliable and reproducible animal models that mimic human pathophysiology are needed. We have tested and expanded the protocols of a wire-injury induced AS mouse model. For this model, coronary wires were used to apply shear stress to the aortic valve cusps with increasing intensity. These protocols allowed distinction of mild, moderate and severe wire-injury. Upon moderate or severe injury, AS developed with a significant increase in aortic valve peak blood flow velocity. While moderate injury promoted solitary AS, severe-injury induced mixed aortic valve disease with concomitant mild to moderate aortic regurgitation. The changes in aortic valve function were reflected by dilation and hypertrophy of the left ventricle, as well as a decreased left ventricular ejection fraction. Histological analysis revealed the classic hallmarks of human disease with aortic valve thickening, increased macrophage infiltration, fibrosis and calcification. This new mouse model of AS promotes functional and morphological changes similar to moderate and severe human AS. It can be used to investigate the pathomechanisms contributing to AS development and to test novel therapeutic strategies.
KeywordsAortic valve stenosis Animal models Inflammation Calcification
We thank Mrs. Theresa Schmitz, Mrs. Anna Flender, Dr. Sandra Adler and Mrs. Katharina Groll for excellent technical assistance. S.N. was funded by Else-Kröner-Fresenius-Foundation of the Medical Faculty of the University of Bonn.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
- 2.Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB (2012) Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 366:1696–1704. https://doi.org/10.1056/NEJMoa1202277 CrossRefGoogle Scholar
- 6.Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, Otto CM, Griffin BP (2007) Clinical factors, but not c-reactive protein, predict progression of calcific aortic-valve disease. The Cardiovascular Health Study. J Am Coll Cardiol 50:1992–1998. https://doi.org/10.1016/j.jacc.2007.07.064 CrossRefGoogle Scholar
- 8.Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791CrossRefGoogle Scholar
- 9.Kim W-K, Blumenstein J, Liebetrau C, Rolf A, Gaede L, Van Linden A, Arsalan M, Doss M, Tijssen JGP, Hamm CW, Walther T, Möllmann H (2017) Comparison of outcomes using balloon-expandable versus self-expanding transcatheter prostheses according to the extent of aortic valve calcification. Clin Res Cardiol 106:995–1004. https://doi.org/10.1007/s00392-017-1149-3 CrossRefGoogle Scholar
- 10.Mauri V, Deuschl F, Frohn T, Schofer N, Linder M, Kuhn E, Schaefer A, Rudolph V, Madershahian N, Conradi L, Rudolph TK, Schäfer U (2018) Predictors of paravalvular regurgitation and permanent pacemaker implantation after TAVR with a next-generation self-expanding device. Clin Res Cardiol 107:688–697. https://doi.org/10.1007/s00392-018-1235-1 CrossRefGoogle Scholar
- 12.Möllmann H, Bestehorn K, Bestehorn M, Papoutsis K, Fleck E, Ertl G, Kuck K-H, Hamm C (2016) In-hospital outcome of transcatheter vs. surgical aortic valve replacement in patients with aortic valve stenosis: complete dataset of patients treated in 2013 in Germany. Clin Res Cardiol 105:553–559. https://doi.org/10.1007/s00392-016-0962-4 CrossRefGoogle Scholar
- 13.Qian J, Chen Z, Ge J, Ma J, Chang S, Fan B, Liu X, Ge L (2010) Relationship between aortic valve calcification and the severity of coronary atherosclerotic disease. J Heart Valve Dis 19:466Google Scholar
- 14.Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjærpe T, Wachtell K, Willenheimer R (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343–1356. https://doi.org/10.1056/NEJMoa0804602 CrossRefGoogle Scholar
- 16.Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O’Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang S-J, Liu Y, Sjogren M, van der Pals J, Kälsch H, Mühleisen TW, Nöthen MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O’Donnell CJ, Post WS (2013) Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368:503–512. https://doi.org/10.1056/NEJMoa1109034 CrossRefGoogle Scholar
- 17.Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM (2011) Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease—2011 update. Circulation 124:1783–1791. https://doi.org/10.1161/CIRCULATIONAHA.110.006767 CrossRefGoogle Scholar
- 20.Honda S, Miyamoto T, Watanabe T, Narumi T, Kadowaki S, Honda Y, Otaki Y, Hasegawa H, Netsu S, Funayama A, Ishino M, Nishiyama S, Takahashi H, Arimoto T, Shishido T, Miyashita T, Kubota I (2014) A novel mouse model of aortic valve stenosis induced by direct wire injury. Arterioscler Thromb Vasc Biol 34:270–278. https://doi.org/10.1161/ATVBAHA.113.302610 CrossRefGoogle Scholar
- 21.Sinning JM, Stundl A, Pingel S, Weber M, Sedaghat A, Hammerstingl C, Vasa-Nicotera M, Mellert F, Schiller W, Kovac J, Welz A, Grube E, Werner N, Nickenig G (2016) Pre-procedural hemodynamic status improves the discriminatory value of the aortic regurgitation index in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 9:700–711. https://doi.org/10.1016/j.jcin.2015.12.271 CrossRefGoogle Scholar
- 22.Hinton RB, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE (2006) Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 98:1431–1438. https://doi.org/10.1161/01.RES.0000224114.65109.4e CrossRefGoogle Scholar
- 24.Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R (2007) Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 116:2841–2850. https://doi.org/10.1161/CIRCULATIONAHA.107.732867 CrossRefGoogle Scholar
- 28.Tkatchenko TV, Moreno-Rodriguez RA, Conway SJ, Molkentin JD, Markwald RR, Tkatchenko AV (2009) Lack of periostin leads to suppression of Notch1 signaling and calcific aortic valve disease. Physiol Genom 39:160–168. https://doi.org/10.1152/physiolgenomics.00078.2009 CrossRefGoogle Scholar